A common germline missense mutation within the APC gene, I1307K, has recently been described in Ashkenazi Jews. We detected this polymorphism in two non-Ashkenazi Jewish women using denaturing gradient gel electrophoresis (DGGE), and hypothesized that in Jewish individuals it might not be restricted to Ashkenazim, and actually reflect a common ancestral polymorphism. To test this notion we performed allelic pattern determination using APC-linked markers in these two women and in nine Ashkenazi carrier controls. The pattern of the intragenic markers, as well as a single downstream marker 30-70 Kb from the APC gene was identical in all individuals, regardless of ethnic origin. We conclude that the I1307K polymorphism in Jewish individuals, is not restricted to Ashkenazim and probably reflects a founder mutation.
Introduction
Inactivating mutations within the APC gene have long been appreciated as underlying the rare familial cancer syndrome familial adenomatous polyposis (FAP). [1] [2] [3] [4] Recently, a novel missense mutation within the APC gene, I1307K, has been described in 28% of Jewish Ashkenazi individuals with familial colorectal cancer and, surprisingly, also in 6% of the general Jewish Ashkenazi population. 5 Mechanistically, this common polymorphism probably facilitates an acquired somatic inactivating mutation in APC, an essential initial step in the development of the adenoma-carcinoma cascade of the colon. 5, 6 Thus far this specific polymorphism has been limited to Jews of east-European (Ashkenazi) extraction. Since we have detected the same mutation in two non-Ashkenazi individuals, one of Turkish and the other of Yemenite origin, we hypothesized that the I1307K polymorphism within the Jewish people may reflect a founder mutation and is not limited to Ashkenazim. Since the occurrence rate of this polymorphism in non-Jewish populations has not been systematically assessed, our observations and conclusions pertain only to Jewish individuals.
Materials and Methods

DNA Extraction
DNA was extracted from peripheral blood leukocytes using standard techniques.
PCRs for Allelic Pattern Determination
Radioactive PCRs were performed in a final volume of 15 µl and contained 32P α dCTP, 10 picomole of each primer, standard 10 ϫ buffer (2.5 mM MgCl2), dNTPs and thermostable DNA polymerase (BioTaq, Appligene-Oncor, Watford, UK). Cycling was achieved in a thermocycler (PTC 100 60, MJ Research Inc., Watertown, MA, USA) using a standard cycling profile, with annealing at 50°C. Following PCR, 5 µl of the product mixed with gel loading buffer were electrophorosed on a 6% gel and autoradiographed for 24-72 h. For non-radioactive PCRs, the final reaction volume was 50 µl, 30 picomoles of each primer were used, and analysing PCR products was done on 1.5% agarose gels with ethidium bromide staining.
Six polymorphic loci from around the APC gene (5ql5-q23) were used, three intragenic markers located at nucleotide positions 1458, 5037 7 and one located within exon 15 (position 5650). 8 One marker (D5S346) is located 30-70 Kb downstream of the gene 9 and two additional markers, D5S299 10 and D5S82 11 proximal to the APC gene. Restriction enzyme digest used for allelic determinations was carried out as previously described 7, 8 with 25 µl of the PCR product digested with a large excess of enzyme for 4 h, to the manufacturer's specified conditions. Digestion products were analysed after size separation on native polyacrylamide gel, as outlined for each specific marker.
7,8
Detection of the I1307K APC Polymorphism by Denaturing Gradient Gel Electrophoresis (DGGE)
Melting Map Analysis The theoretical melting profile of the amplified fragment (from position 3902 to position 4304 of exon 15 of the APC gene) was generated using the Macmelt software, according to the algorithm of Lerman and co-workers. 12 PCR These PCRs were done in a final reaction volume of 50 µl containing 0.5U thermostable DNA polymerase, 10 ϫ standard PCR buffer (2.5mM MgCl), 200 nM of dNTPs, with 20 picomoles of each of the following primers:
Cycling was achieved in the same thermocycler as above, using a standard cycling profile with annealing at 56°C for 1 min. Following PCR, 10% of the product was analysed on a 1.5% agarose gel to ensure specificity and success of the reaction.
DGGE Parallel denaturing gradient gels with a denaturant range of 20-60% were cast and run using the D Gene apparatus (Bio-Rad, Richmond, CA, USA), according to the method of Myers and co-workers. 13 15-25 µl of the PCR reaction were loaded on to the gels, electrophorosed at 40 mAmp (58C) for 16 h, and stained with ethidium bromide.
Direct Sequencing DNA sequencing of the PCR products were formed after purification of the product by the Wizard Kit (Promega, Madison, WI, USA), and employing the Thermo Sequenase radiolabelled terminator cycle sequencing kit (Amersham Life Sciences, Piscataway, NJ, USA) according to the manufacturer's recommendations.
Results
Patients' Characteristics
All analysed patients had pathologically proven breast cancer, screened for being a carrier of the I1307K APC polymorphism, as part of a larger, current study.
14 Upon repeated questioning, there was no doubt as to the non-Ashkenazi origin of the two individuals, at least four generations back. As controls, we used DNA obtained from 43 Ashkenazi and 42 Yemenite individuals, not selected for any disease, who volunteered to donate blood as 'ethnic controls'. The ethnic origin of these individuals was ascertained at least three generations back. In addition, a single Ashkenazi family with a father who had colon cancer, and four of his daughters, two of whom had breast cancer, were also analysed.
I1307K APC Mutation Carriers
The presence of the I1307K was heralded by an abnormal migration pattern on DGGE ( Figure 1A) . As is evident, this migration pattern abnormality is compatible with a heterozygous sequence alteration, as indeed, direct DNA sequencing of these individuals, showed the I1037K polymorphism in all samples ( Figure 1B) .
Allelic Pattern Determination
Allelic pattern analysis of six markers close to the APC gene, three being intragenic, is depicted in Figure 2A and Figure 2B . All mutation carriers, Ashkenazi and non-Ashkenazi alike, shared a common allelic pattern in the three intragenic markers and the one 30-70 Kb downstream of it. Differences were detected between mutation carriers, even among Ashkenazi mutation carriers, with the more proximal markers, D5S82 and D5S299. In the family analysed ( Figure 2C ) both affected sisters who were APC I1307K carriers, shared an allele with the father, and the haplotype seen in these individuals was compatible with the 'common' four-allele pattern seen in all other mutation carriers. This 'common' four-marker haplotype was detected in 18/43 (41%) unselected Ashekenazi Jews and in 10/42 (23.4%) unselected Yemenite Jews (data not shown).
Discussion
The I1307K APC polymorphism has been detected in two non-Ashkenazi individuals, and the allelic pattern of these mutation carriers was identical with that of nine Ashkenazi mutation carriers with intragenic APC markers and D5S346, the downstream marker. Furthermore, this 'common haplotype' was also shown to exist in a single Ashkenazi family. Several possibilities may account for this observation. First, the ethnic origin of the non-Ashkenazis was, in fact, Ashkenazi. This seems highly unlikely given the ascertainment of their pedigrees four generations back and to some extent their physical features. Furthermore, whilst there was a constant migration and mixing between the Jewish communities in Turkey and East Europe, the Yemenite population remained segregated with no real ties with the Ashkenazi population of East Europe. 15, 16 However, an Ashkenazi marrying into any of these two families earlier than can possibly be ascertained cannot be ruled out completely. Second, it might be that the polymorphism with this specific haplotype originated early in the history of the Jewish people, prior to the dispersion of the Yemenite Jews, circa 500 BC. 15, 16 Little has been published about the notion of a founder effect in APC mutation carriers. No founder mutations were detected in ethnically diverse codon 1309 AAAGA (3926del5) mutation carriers, 17 including a single Israeli patient. In contrast, evidence for a common haplotype was reported in unrelated Portuguese families. 18 Published analyses of unrelated, ethnically diverse Israeli APC families, did not elaborate on the possibility of a common founder. 19 A divergence in the common haplotype was detected in Ashkenazi and non-Ashkenazi carriers using markers D5S82 and D5S299. This is not surprising given the distances of these markers from the APC gene itself, with recombination rates of 0.08-0.1%, and an estimated physical distance of the D5S82 marker of more than 100 Kb from the gene itself. Thus, the region of APC that seems to be common to Ashkenazi and non-Ashkenazi mutation carriers, span the gene itself and at least 30 Kb telomeric to it.
We have also shown the ability of denaturing gradient gel electrophoresis (DGGE) to detect the I1307K polymorphism. Application of DGGE to this specific polymorphism is important, given the clustering of somatic mutations in the area immediately flanking codon 1307. 5 Given the sensitivity and specificity of From the clinical perspective, it seems that similar to the inherited susceptibility to breast and ovarian cancer in the Jewish people, the predominant sequence alteration in APC amongst Jewish people is not limited to the Ashkenazi population, and that genetic testing for this specific mutation should be offered to familial colorectal cancer Jewish individuals, regardless of ethnic origin. It should be re-emphasised that these conclusions should only be applied to Jewish individuals, as the rate of this specific polymorphism in non-Jewish populations, is still to be systematically evaluated.
